-

Notice of Capital and Business Alliance Between Heartseed and MEDIPAL HOLDINGS

-Cooperation in Product Development for Innovative Cardiac Regenerative Medicine-

TOKYO--(BUSINESS WIRE)--Tokyo-based Heartseed Inc. (“Heartseed”), a Keio University-originated biotechnology company developing induced pluripotent stem cell (iPSC)-derived cardiac regenerative medicine, and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have entered into a capital and business alliance.

In conjunction with the alliance, MEDIPAL will acquire an equity stake in Heartseed. In addition, MEDIPAL and its wholly owned subsidiary SPLine Corporation (“SPLine”) will begin collaborative research with Heartseed on the logistics of Heartseed’s clinical trial supplies.

Purpose of the Alliance

Heartseed is developing HS-001, allogeneic iPSC-derived cardiomyocyte spheroids for severe heart failure, which currently has no effective treatment other than heart transplantation. In preparation for the initiation of its clinical trial, Heartseed will outsource its manufacturing to Nikon CeLL innovation Co., Ltd., and are discussing transport of the cardiomyocyte spheroids with MEDIPAL.

MEDIPAL has established a distribution system in compliance with Japanese Good Distribution Practice (GDP) guidelines. MEDIPAL is a pioneer in logistics services in the growing field of regenerative medicine, and has an extensive track record to support development of regenerative medicine products and to build a logistics system for them using its ultra-low temperature transport system.

In this alliance, MEDIPAL will contribute to the improvement of patient care by promoting development of Heartseed’s innovative products from the clinical trial stage with its experience and expertise in the distribution of regenerative medicine products.

For more information, please visit http://www.heartseed.jp/en/index.html#pipeline

Contacts

For Heartseed, Inc.:
Kikuo Yasui, COO
Tel: +81-3-6380-1068

For MEDIPAL HOLDINGS CORPORATION:
Corporate Planning and Public Relations Department
Tel: +81-3-3517-5171

Industry:

Heartseed Inc.

Release Summary
Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS
Release Versions
English
Hashtags
#biotech
#bioventure
#cardiomyocyte
#celltherapy
#fundraising
#heartfailure
#iPS
#regenerativemedicine
#stemcell

Contacts

For Heartseed, Inc.:
Kikuo Yasui, COO
Tel: +81-3-6380-1068

For MEDIPAL HOLDINGS CORPORATION:
Corporate Planning and Public Relations Department
Tel: +81-3-3517-5171

Social Media Profiles
HEARTSEED on LinkedIn
More News From Heartseed Inc.

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

TOKYO & PALO ALTO, Calif.--(BUSINESS WIRE)--Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed's proprietary cardiomyocytes differentiation and purification methods. As a result, Heartseed has successfully produced high-puri...

Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

TOKYO--(BUSINESS WIRE)--Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology (JCC) on September 9, 2023. Dr. Yuki Ichihara, Departmen...

Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy

TOKYO--(BUSINESS WIRE)--Heartseed Inc. (CEO: Keiichi Fukuda) today announced that it has entered into a worldwide non-exclusive patent license agreement (“Agreement”) with an undisclosed biotech company (“Licensee”) for its Metabolic Selection technology, a proprietary platform used to selectively remove undifferentiated induced pluripotent stem cells (iPSCs). This technology addresses the need to eliminate potentially tumor-causing undifferentiated iPSCs as the clinical use of iPSC-based cell...
Back to Newsroom